Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Drug delivery to the brain is greatly hampered by the presence of the blood-brain barrier (BBB) which tightly regulates the passage of molecules from blood to brain and vice versa. Nanocarriers, in which drugs can be encapsulated, can move across the blood-brain barrier (BBB) via the process of transcytosis, thus showing promise to improve drug delivery to the brain. Here, we demonstrate the use of natural nanovesicles, that is, exosomes, derived from C17.2 neural stem cells (NSCs) to efficiently carry a protein cargo across an in vitro BBB model consisting of human brain microvascular endothelial cells. We show that the exosomes are primarily taken up in brain endothelial cells via endocytosis, while heparan sulfate proteoglycans (HSPGs) act as receptors. Taken together, our data support the view that NSC exosomes may act as biological nanocarriers for efficient passage across the BBB. Nanomedicines that target HSPGs may improve their binding to brain endothelial cells and, possibly, show subsequent transcytosis across the BBB.
Pubmed ID: 32939863
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Cell line C17.2 is a Transformed cell line with a species of origin Mus musculus (Mouse)
View all literature mentionsThis polyclonal targets
View all literature mentionsThis polyclonal targets IgG
View all literature mentionsThis polyclonal secondary targets IgG, IgM (H+L)
View all literature mentionsThis polyclonal targets SDC2
View all literature mentionsThis polyclonal targets IgG
View all literature mentionsThis monoclonal targets TSG101
View all literature mentionsThis monoclonal targets CD9 antibody [EPR2949]
View all literature mentionsThis polyclonal targets RCJMB04_4h19
View all literature mentions